Accès ouvert
2025
article
OpenAlex
Lisanne A. H. Bevers, Gabriela Toledo, Muzamil Kisekka, Isabelle Déprez et autres
Background Two-drug regimen dolutegravir/lamivudine (DTG/3TC) is recommended as an alternative to standard three-drug regimens in adult treatment guidelines. This nested pharmacokinetic sub-study within the D3/Penta 21 randomised trial (#NCT04337450) assessed DTG and 3TC concentrations and safety in virologically-suppressed children, switching to once-daily …
nl, gb, Ouganda, ca, Afrique du Sud, it
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Anna Turkova, Ellen White, Adeodata Kekitiinwa, Vivian Mumbiro et autres
BACKGROUND: Cohort studies in adults with HIV showed that dolutegravir was associated with neuropsychiatric adverse events and sleep problems, yet data are scarce in children and adolescents. We aimed to evaluate neuropsychiatric manifestations in children and adolescents treated with dolutegravir-based treatment versus …
gb, Ouganda, Zimbabwe, Afrique du Sud, th, de, es, fr, it
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Alexandra Compagnucci, Man K. Chan, Yacine Saïdi, Tim R. Cressey et autres
Background Integrase inhibitor (INSTI) with boosted darunavir (DRV/r), a regimen with a high-resistance barrier, avoiding NRTI toxicities, might be a switching option in children living with HIV (CLWHIV). Methods SMILE is a randomised non-inferiority trial evaluating safety and antiviral efficacy of once-daily …
fr, gb, th, it, Ouganda, Afrique du Sud, ua, ar, pa, mx, es, ch, pt, de
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Pauline Amuge, Abbas Lugemwa, Ben Wynne, Hilda Mujuru et autres
BACKGROUND: Young children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg. METHODS: ODYSSEY is an open-label, randomised, non-inferiority trial …
Ouganda, gb, Zimbabwe, Afrique du Sud, it, es
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Anna Turkova, Hylke Waalewijn, Man K. Chan, Pauline Bollen et autres
BACKGROUND: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB. METHODS: on the first substudy day. All children within ODYSSEY with …
gb, nl, Zimbabwe, Ouganda, Afrique du Sud, th, us
(code pays fourni par la source)